Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anadys Pharmaceuticals, Inc. is staying mum about its partnering prospects, but the biotech clearly thinks promising Phase IIb data for setrobuvir (ANA598), its polymerase inhibitor for genotype 1 hepatitis C, could move it to the head of the class.